Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Subcutaneous immunoglobulin for the treatment of deep morphoea in a child

Subcutaneous immunoglobulin for the treatment of deep morphoea in a child Morphoea, also known as localized scleroderma, is a disorder characterized by excessive collagen deposition leading to thickening of the dermis and/or subcutaneous tissues. Intravenous IgG therapy has induced improvement in some fibrotic conditions. The primary indication for subcutaneous IgG (SCIG) is in primary immunodeficiency disorders as replacement therapy; however, recently there has been considerable interest in SCIG as an immunomodulatory agent. We report an 11‐year‐old girl with deep morphoea who was successfully treated with SCIG. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical & Experimental Dermatology Wiley

Loading next page...
1
 
/lp/wiley/subcutaneous-immunoglobulin-for-the-treatment-of-deep-morphoea-in-a-fJCpPWNl2A

References (10)

Publisher
Wiley
Copyright
Copyright © 2018 British Association of Dermatologists
ISSN
0307-6938
eISSN
1365-2230
DOI
10.1111/ced.13352
pmid
29280519
Publisher site
See Article on Publisher Site

Abstract

Morphoea, also known as localized scleroderma, is a disorder characterized by excessive collagen deposition leading to thickening of the dermis and/or subcutaneous tissues. Intravenous IgG therapy has induced improvement in some fibrotic conditions. The primary indication for subcutaneous IgG (SCIG) is in primary immunodeficiency disorders as replacement therapy; however, recently there has been considerable interest in SCIG as an immunomodulatory agent. We report an 11‐year‐old girl with deep morphoea who was successfully treated with SCIG.

Journal

Clinical & Experimental DermatologyWiley

Published: Jan 1, 2018

There are no references for this article.